Circio Holding ASA – Mandatory notification of trade by primary insiders and close associates related to the rights issue and private placement
Summary by AI BETAClose X
Circio Holding ASA has announced the final results of its rights issue and private placement, with key primary insiders and their close associates receiving allocations of new shares and warrants. Notably, CEO Erik Digman Wiklund, COO Ola Melin, CTO Thomas Birkballe Hansen, CFO Lubor Gaal's associated company BioPharma Drug Licensing Group SL, CSO Victor Levitsky, board member Thomas Falck's associate Sølen AS, board member Diane Mary Mellett, and Chairman Damian Marron all participated in these allocations, with some also receiving additional shares and warrants as commission for pre-subscriptions.
NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.
Oslo, 30 January 2026: Reference is made to the stock exchange announcement published by Circio Holding ASA (the “Company”) earlier today, 30 January 2026, regarding the final results of the rights issue and the private placement.
The following primary insiders and close associates to primary insiders have been allocated new shares and warrants in the Rights Issue and Private Placement, including new shares and warrants as commission for their pre-subscriptions in the Rights Issue:
- Erik Digman Wiklund, the CEO of the Company, has been allocated 150,000 new shares and the corresponding number of warrants in the Rights Issue and private placement. In addition, Erik Digman Wiklund has been granted 44,000 new shares and the corresponding number of warrants as commission for his pre-subscription in the Rights Issue.
- Digman AS, a company closely associated with Erik Digman Wiklund, the CEO of the Company, has been allocated 250,000 new shares and the corresponding number of warrants in the Rights Issue and private placement.
- Ola Melin, Chief Operating Officer of the Company, has been allocated 150,000 new shares and the corresponding number of warrants in the Rights Issue and private placement. In addition, Ola Melin has been granted 16,500 new shares and the corresponding number of warrants as commission for his pre-subscription in the Rights Issue.
- Thomas Birkballe Hansen, Chief Technology Officer of the Company, has been allocated 200,000 new shares and the corresponding number of warrants in the Rights Issue and private placement. In addition, Thomas Birkballe Hansen has been granted 22,000 new shares and the corresponding number of warrants as commission for his pre-subscription in the Rights Issue.
- BioPharma Drug Licensing Group SL (“BioPharma”), a company closely associated with Lubor Gaal, the CFO of the Company, has been allocated 270,000 new shares and the corresponding number of warrants in the Rights Issue and private placement. In addition, Biopharma has been granted 29,700 new shares and the corresponding number of warrants as commission for pre-subscription in the Rights Issue.
- Victor Levitsky, Chief Scientific Officer of the Company, has been allocated 250,000 new shares and the corresponding number of warrants in the Rights Issue and private placement. In addition, Victor Levitsky has been granted 27,500 new shares and the corresponding number of warrants as commission for his pre-subscription in the Rights Issue.
- Sølen AS, a close associate of Thomas Falck, board member of the board of directors of the Company, has been allocated 200,000 new shares, and the corresponding number of warrants in the Rights Issue and private placement. In addition, Sølen AS has been granted 22,000 new shares and the corresponding number of warrants as commission for pre-subscription in the Rights Issue.
- Diane Mary Mellett, board member of the board of directors of the Company, has been allocated 60,000 new shares and the corresponding number of warrants in the Rights Issue and private placement. In addition, Diane Mary Mellet has been granted 6,600 new shares and the corresponding number of warrants as commission for her pre-subscription in the Rights Issue.
- Robert Forbes Burns, deputy member of the board of directors of the Company, has been allocated 11,542 new shares and the corresponding number of warrants in the Rights Issue and private placement.
- Damian Marron, the Chairman of the board of directors of the Company, has been allocated 120,000 new shares and the corresponding number of warrants in the Rights Issue and private placement. In addition, Damian Marron has been granted 13,200 new shares and the corresponding number of warrants as commission for his pre-subscription in the Rights Issue.
Please see the attached notifications of trade for information regarding the subscription rights exercised by primary insiders in the Rights Issue and Private Placement.
Latest directors dealings
- 53 minutes ago Croda International
- 1 hour ago Diageo
- 1 hour ago IMI
- 2 hours ago Softcat
- 5 hours ago Tertiary Minerals